Boxer Capital Management LLC Takes Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Boxer Capital Management LLC bought a new stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 650,000 shares of the company's stock, valued at approximately $3,790,000. Boxer Capital Management LLC owned about 1.13% of Olema Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in OLMA. Charles Schwab Investment Management Inc. boosted its holdings in Olema Pharmaceuticals by 0.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 332,950 shares of the company's stock worth $1,941,000 after acquiring an additional 2,189 shares in the last quarter. Boothbay Fund Management LLC boosted its stake in Olema Pharmaceuticals by 10.8% in the 4th quarter. Boothbay Fund Management LLC now owns 31,226 shares of the company's stock worth $182,000 after purchasing an additional 3,056 shares in the last quarter. Virtus ETF Advisers LLC grew its position in Olema Pharmaceuticals by 43.1% during the 4th quarter. Virtus ETF Advisers LLC now owns 10,579 shares of the company's stock valued at $62,000 after purchasing an additional 3,185 shares during the last quarter. SG Americas Securities LLC raised its holdings in Olema Pharmaceuticals by 33.8% in the 4th quarter. SG Americas Securities LLC now owns 17,475 shares of the company's stock worth $102,000 after acquiring an additional 4,419 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in shares of Olema Pharmaceuticals during the fourth quarter valued at $30,000. 91.78% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

OLMA has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 target price on shares of Olema Pharmaceuticals in a research report on Monday, April 28th. JPMorgan Chase & Co. lowered their target price on Olema Pharmaceuticals from $30.00 to $28.00 and set an "overweight" rating on the stock in a report on Friday, March 28th. Finally, Oppenheimer reiterated an "outperform" rating and issued a $25.00 price objective (down previously from $30.00) on shares of Olema Pharmaceuticals in a research note on Wednesday, March 19th.

Olema Pharmaceuticals Trading Down 0.9 %

Olema Pharmaceuticals stock traded down $0.04 during trading on Wednesday, reaching $4.56. The company had a trading volume of 221,072 shares, compared to its average volume of 869,967. The firm's 50-day simple moving average is $4.25 and its 200 day simple moving average is $6.48. Olema Pharmaceuticals, Inc. has a 52 week low of $2.86 and a 52 week high of $16.62. The firm has a market capitalization of $311.73 million, a price-to-earnings ratio of -2.08 and a beta of 2.03.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($0.51) earnings per share for the quarter, beating analysts' consensus estimates of ($0.63) by $0.12. On average, analysts predict that Olema Pharmaceuticals, Inc. will post -2.33 earnings per share for the current year.

Olema Pharmaceuticals Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.